- Home
- ADPT vs NXRT Comparison
ADPT vs NXRT Comparison
Compare ADPT & NXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- NXRT
- Stock Information
- Founded
- ADPT 2009
- NXRT 2014
- Country
- ADPT United States
- NXRT United States
- Employees
- ADPT N/A
- NXRT N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- NXRT Real Estate Investment Trusts
- Sector
- ADPT Health Care
- NXRT Real Estate
- Exchange
- ADPT Nasdaq
- NXRT Nasdaq
- Market Cap
- ADPT 1.1B
- NXRT 911.6M
- IPO Year
- ADPT 2019
- NXRT N/A
- Fundamental
- Price
- ADPT $7.33
- NXRT $36.49
- Analyst Decision
- ADPT Strong Buy
- NXRT Buy
- Analyst Count
- ADPT 5
- NXRT 6
- Target Price
- ADPT $9.40
- NXRT $46.33
- AVG Volume (30 Days)
- ADPT 2.4M
- NXRT 185.9K
- Earning Date
- ADPT 05-01-2025
- NXRT 04-29-2025
- Dividend Yield
- ADPT N/A
- NXRT 5.59%
- EPS Growth
- ADPT N/A
- NXRT N/A
- EPS
- ADPT N/A
- NXRT 0.04
- Revenue
- ADPT $178,957,000.00
- NXRT $259,873,000.00
- Revenue This Year
- ADPT $21.20
- NXRT $0.06
- Revenue Next Year
- ADPT $22.06
- NXRT $5.96
- P/E Ratio
- ADPT N/A
- NXRT $842.80
- Revenue Growth
- ADPT 5.10
- NXRT N/A
- 52 Week Low
- ADPT $2.28
- NXRT $30.73
- 52 Week High
- ADPT $9.01
- NXRT $48.37
- Technical
- Relative Strength Index (RSI)
- ADPT 43.95
- NXRT 46.60
- Support Level
- ADPT $7.38
- NXRT $35.38
- Resistance Level
- ADPT $8.30
- NXRT $36.21
- Average True Range (ATR)
- ADPT 0.75
- NXRT 1.71
- MACD
- ADPT -0.04
- NXRT 0.02
- Stochastic Oscillator
- ADPT 33.85
- NXRT 56.22
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.